Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Operating Income (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Operating Income readings, the most recent being $61.2 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 397.41% to $61.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.0 million, a 94.37% increase, with the full-year FY2025 number at -$5.0 million, up 94.37% from a year prior.
  • Operating Income hit $61.2 million in Q4 2025 for Aligos Therapeutics, up from -$28.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $61.2 million in Q4 2025 to a low of -$37.9 million in Q4 2021.
  • Median Operating Income over the past 5 years was -$22.4 million (2022), compared with a mean of -$20.4 million.
  • The widest YoY moves for Operating Income: up 397.41% in 2025, down 40.88% in 2025.
  • Aligos Therapeutics' Operating Income stood at -$37.9 million in 2021, then skyrocketed by 40.23% to -$22.7 million in 2022, then decreased by 14.62% to -$26.0 million in 2023, then grew by 20.9% to -$20.6 million in 2024, then soared by 397.41% to $61.2 million in 2025.
  • The last three reported values for Operating Income were $61.2 million (Q4 2025), -$28.4 million (Q3 2025), and -$18.6 million (Q2 2025) per Business Quant data.